RED+BLUE STRATEGIES for PEW CHARITABLE TRUSTS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to end of life, palliative care and policies related to hospice programs. Issues related to antibiotic innovation and advancement Issues related to monograph reform. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Medicare/Medicaid MMM
S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. Issues related to end of life, palliative care and policies related to hospice programs. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to the Physician Payment Sunshine Act and the Open Payments system.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Pharmacy PHA
S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.